Rifaximin

Rifaximin is approved in the United States for the treatment of irritable bowel syndrome. It possesses anti-inflammatory and antibacterial properties, and is a nonabsorbable antibiotic that acts locally in the gut. These properties make it efficacious in relieving chronic functional symptoms of non-constipation  type irritable bowel syndrome (IBS).It is based on rifamycin. Rifaximin was approved for medical use in the United States in May 2004.